Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4096| Title: | A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium | Authors: | Triche, T. Sposto, R. Yang, X. Bittencourt, H. Place, A. E. Messinger, Y. Fraser, C. Dalla-Pozza, L. Salhia, B. Jones, P. Wayne, A. S. Gore, L. Cooper, T. M. Liang, G. Sun, W. Gaynon, P. Malvar, J. |
Issue Date: | 2018 | Source: | 131, (10), 2018, p. 1145-1148 | Pages: | 1145-1148 | Journal: | Blood | Abstract: | L6223106042018-06-05 | DOI: | 10.1182/blood-2017-09-803809 | Resources: | https://www.embase.com/search/results?subaction=viewrecord&id=L622310604&from=exporthttp://dx.doi.org/10.1182/blood-2017-09-803809 | | Keywords: | drug efficacy;drug safety;febrile neutropenia;gene expression profiling;genetic association;hematopoietic stem cell transplantation;human;hypokalemia;hyponatremia;hypophosphatemia;infection;infestation;letter;leukemia remission;leukocyte count;lymphocyte count;multicenter study (topic);multiple cycle treatment;neutrophil count;oral bleeding;pain;phase 1 clinical trial;phase 2 clinical trial (topic);platelet count;priority journal;randomized controlled trial (topic);side effect;stomatitis;treatment response;sepsis;NCT01861002alanine aminotransferase;aspartate aminotransferase;azacitidine;bilirubin;contig;cytarabine;daunorubicin;decitabine;etoposide;farnesyl transferase 1;fludarabine;protein farnesyltransferase;tumor marker;unclassified drug;acute lymphoblastic leukemia;acute myeloid leukemia;alanine aminotransferase blood level;anorexia;aspartate aminotransferase blood level;bilirubin blood level;cancer combination chemotherapy;child;childhood leukemia;clinical article;clinical outcome;cohort analysis;CpG island;de novo acute myeloid leukemia;DNA methylation | Type: | Article |
| Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.